Conjugates of PSMA-binding moieties with cytotoxic agents
AssigneePhilochem AG
InventorsGabriele Bassi, Samuele Cazzamalli, Tony Georgiev, Aureliano Zana, Dario Neri
Life of this patent
Estimating the term…
Loading patent…
AssigneePhilochem AG
InventorsGabriele Bassi, Samuele Cazzamalli, Tony Georgiev, Aureliano Zana, Dario Neri
Estimating the term…
A conjugate of Formula I or a pharmaceutically acceptable salt thereof, wherein: PB is a PSMA binding moiety which has a molecular weight of below 1000 Da; L1 is a linker covalently attaching PB to Gly-Pro, said linker being a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a length between 6 and 30 atoms (via the shortest path between PB and Gly-Pro) between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; L2 is a either a single bond or a self-immolative linker; and Drug is a cytotoxic agent linked to Gly-Pro.
A conjugate of Formula I:
A method of treatment of a subject suffering from a disease characterized by PSMA overexpression comprising administering a therapeutically effective amount of a conjugate of Formula I or a pharmaceutically acceptable salt thereof to a subject suffering from said disease wherein:
Dependencies are inferred from the claim text.